![Jonathan Burgin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jonathan Burgin
Vorstandsvorsitzender bei BioCancell Therapeutics, Inc.
Profil
Jonathan Burgin's current job is as the Chief Executive Officer at BioCancell Therapeutics, Inc. He previously held positions as the Director-Investor Relations at XTL Biopharmaceuticals Ltd., Independent Director at Cellect Biotechnology Ltd., Chief Financial Officer at RADCOM Ltd., Chief Operating Officer at Anchiano Therapeutics Ltd., and Senior Manager at Kesselman & Kesselman.
Prior to these roles, he was a Member at PricewaterhouseCoopers International Ltd.
and Chief Financial Officer at Y.L.R.
Capital Markets Ltd.
Mr. Burgin obtained his undergraduate degree and MBA from Tel-Aviv University.
Aktive Positionen von Jonathan Burgin
Unternehmen | Position | Beginn |
---|---|---|
BioCancell Therapeutics, Inc.
![]() BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Vorstandsvorsitzender | 04.06.2012 |
Ehemalige bekannte Positionen von Jonathan Burgin
Unternehmen | Position | Ende |
---|---|---|
ANCHIANO THERAPEUTICS LTD. | Vorstandsvorsitzender | 19.10.2016 |
RADCOM | Finanzdirektor/CFO | 21.05.2011 |
XTL BIOPHARMACEUTICALS LTD. | Public Communications Contact | 01.01.2006 |
Y.L.R. Capital Markets Ltd. | Finanzdirektor/CFO | 01.01.1999 |
PricewaterhouseCoopers International Ltd.
![]() PricewaterhouseCoopers International Ltd. Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers International Ltd. operates as an international association of accounting and consultancy firm. The company was founded on June 24, 1998 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Jonathan Burgin
Tel-Aviv University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
RADCOM | Technology Services |
XTL BIOPHARMACEUTICALS LTD. | Health Technology |
Private Unternehmen | 6 |
---|---|
Anchiano Therapeutics Ltd.
![]() Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
Kesselman & Kesselman
![]() Kesselman & Kesselman Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Kesselman & Kesselman is an Israeli company that provides accounting services. The company is based in Tel Aviv, Israel. | Commercial Services |
PricewaterhouseCoopers International Ltd.
![]() PricewaterhouseCoopers International Ltd. Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers International Ltd. operates as an international association of accounting and consultancy firm. The company was founded on June 24, 1998 and is headquartered in London, the United Kingdom. | Commercial Services |
BioCancell Therapeutics, Inc.
![]() BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Health Technology |
Y.L.R. Capital Markets Ltd. | |
Cellect Biotechnology Ltd.
![]() Cellect Biotechnology Ltd. Medical SpecialtiesHealth Technology Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel. | Health Technology |